Skip to main content
    C

    CareDx Inc (CDNA)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $73.72
    -4.16 (-5.34%)

    Market Cap: $4.09B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CareDx Inc (CDNA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    CareDx (CDNA) trades at 48.2x trailing earnings and 6.4x sales. Its P/S of 6.4x is above its 5-year median of 2.7x. Its forward P/E is 68.5x. The median P/E across 7 similar companies is 20.5x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 29.6% lower over the next year. Its free cash flow yield is 2.2%.

    MultipleValue
    P/E (trailing)48.2x
    Forward P/E68.5x
    Price to sales6.4x
    Price to book8.9x
    EV/EBITDA26.2x
    Price to FCF44.8x
    EV/FCF40.4x
    PEGN/A
    FCF yield2.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 73.0% above 3.7x and its P/B is 107.0% above 4.3x.

    MultipleCurrent5-year median10-year median
    P/S6.4x2.7x3.7x
    P/B8.9x2.7x4.3x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 114 to 120 months (10-year).

    Valuation History

    Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 31.4x in 2025 to 905.6x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$18.8431.4x2.6x3.2x
    2024$21.4139.6x3.4x3.3x
    2023$12.00N/A2.3x2.4x
    2022$11.41N/A1.9x1.4x
    2021$45.48156.8x8.0x5.2x
    2020$72.45905.6x18.0x12.9x
    2019$21.57N/A7.2x9.3x
    2018$25.14N/A11.8x10.5x
    2017$7.34N/A3.5xN/A
    2016$2.70N/A1.1x2.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CDNA

    What is CDNA's forward P/E ratio?

    CareDx has a forward P/E ratio of 68.5x.

    Is CDNA stock overvalued?

    GNG's valuation label for CDNA is Overvalued. Its P/E of 48.2x compares with a median of 20.5x across 7 similar companies.

    What is CDNA's price to sales ratio?

    CareDx has a price to sales ratio of 6.4x.